SCOTUS Declines McKenna West Case as Surrogacy Pressure Mounts Globally

The U.S. Supreme Court, through Justice Elena Kagan, declined to hear surrogate McKenna West's emergency appeal to block the California intended parents from taking custody of the baby boy. The decision leaves standing a California court's parentage ruling in favor of the Los Angeles couple. The case, which has drawn national attention since Texas courts became entangled in the dispute, now moves forward without federal high court involvement.

The Supreme Court's refusal to step in is a meaningful signal, though it is not a ruling on the underlying legal questions. This case will continue to shape how courts in conflicting jurisdictions handle surrogacy agreements, so it is still worth following closely.

WIRED published a deep profile of a 28-year-old religious activist who has become a prominent force opposing IVF and surrogacy access across the United States. The piece examines how she has worked to influence legislation and public opinion, and how her efforts have intersected with ongoing state-level debates over reproductive technology. The profile raises questions about the growing organized opposition to assisted reproduction as a legal and political category.

This one is worth reading in full. The profile is a reminder that the regulatory environment around IVF and surrogacy is not shaped only by courts and clinics. Understanding who is organizing opposition, and how, is useful context for anyone navigating these processes right now.

The Stanford Review reports that a former Stanford Hoover Institution fellow runs a surrogacy firm that has been helping wealthy Chinese clients have U.S.-citizen children through American surrogates. The piece adds a new institutional dimension to ongoing coverage of how Chinese elites are using U.S. surrogacy agencies, connecting the practice to elite academic and policy circles. NDTV also published a broader explainer on the same day detailing how the system operates.

This story adds an elite-network layer to a case that has already drawn congressional attention. The firm-level details matter for intended parents and surrogates who want to understand the range of actors currently under scrutiny in this space.

The Philippines Bureau of Immigration published a statement confirming it had foiled a suspected surrogacy trafficking scheme that was routing women to the country of Georgia. The release adds official detail to earlier reporting on the BI's crackdown, including specifics about how the operation was structured and intercepted. The Philippines has been conducting a sustained enforcement campaign against unregulated surrogacy networks.

Worth watching, particularly for anyone considering international surrogacy arrangements routed through Southeast Asia. Enforcement actions like this can disrupt in-progress arrangements without warning.

Embryo Genetic Testing: PGT-A and What It Reveals

When a fertility clinic creates embryos through IVF, one of the most meaningful decisions a care team and their patients face together is whether to test those embryos before transfer. Preimplantation genetic testing for aneuploidies — known as PGT-A — is a screening tool designed to look at an embryo's chromosomes and count whether the right number are present.

Human cells are meant to carry 46 chromosomes, arranged in 23 pairs. An embryo with the correct count is called euploid, meaning it has the chromosomal balance most likely to support a healthy pregnancy. An embryo with too many or too few chromosomes is called aneuploid. Aneuploidy is actually quite common in embryos created through IVF, particularly as the egg donor or intended mother grows older, and it is a leading reason why transfers sometimes do not result in pregnancy or end in early miscarriage.

To perform PGT-A, an embryologist carefully removes a small cluster of cells — usually five to ten — from the outer layer of the embryo on day five or six of development, a stage called the blastocyst. These cells are the ones destined to become the placenta, not the baby itself, which is an important reassurance for many families. The biopsy sample is then sent to a genetics laboratory, where technicians analyze the chromosomal makeup and return a report categorizing each embryo.

The debate among reproductive endocrinologists is a real and ongoing one. Some specialists strongly recommend PGT-A for all IVF cycles because it helps prioritize the most viable embryos. Others caution that the test is not perfect — a small number of embryos may be incorrectly categorized, and some aneuploid embryos have been known to self-correct. Talking openly with your medical team about your specific circumstances is the most reliable way to decide whether PGT-A is right for your journey.